Affordable Access

deepdyve-link deepdyve-link
Publisher Website

IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.

Authors
  • Lorenc, Z Paul
  • Kenkel, Jeffrey M
  • Fagien, Steven
  • Hirmand, Haideh
  • Nestor, Mark S
  • Sclafani, Anthony P
  • Sykes, Jonathan M
  • Waldorf, Heidi A
Type
Published Article
Journal
Aesthetic Surgery Journal
Publisher
Oxford University Press
Publication Date
Mar 01, 2013
Volume
33
Issue
1 Suppl
Identifiers
DOI: 10.1177/1090820X12474633
PMID: 23515195
Source
Medline
License
Unknown

Abstract

IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.

Report this publication

Statistics

Seen <100 times